Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Abemaciclib (Primary) ; Clarithromycin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 18 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Feb 2015 as reported by ClinicalTrials.gov record.